

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human Kallikrein 12 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross-reactivity with recombinant human (rh) Kallikrein 8, rhKallikrein 10, rhKallikrein 11, and rhKallikrein 12
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Kallikrein 12 Ala18-Asn248 Accession # Q9UKR0
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.
Immunoprecipitation	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Human tissue Kallikrein 12, encoded by the KLK12 gene, is a secreted serine protease that belongs to the human tissue kallikrein family. It is present in many tissues, such as salivary gland, stomach and breast. KLK12 displays trypsin-like enzymatic activity. This activity can be inhibited by Serpin F2 (R&D Systems, Catalog # 1470-PI). The physiological functions of KLK12 still remain unclear. Its expression is modulated by steroid hormones and is down-regulated in breast cancer (2). Human KLK12 has three splice variants resulting from alternative splicing of the 3' end. The KLK12 produced by the R&D Systems corresponds to the full-length classical form, also known as isoform 2 (1). The amino acid sequence of human KLK12 is 80%, 77%, 71% and 66% to that of bovine, canine, mouse, and rat. The recombinant human KLK12 can be autoactivated under the conditions described in the Activity Assay Protocol. The active enzyme has the N-terminal sequence of I₂₂FNGTECGRNS.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc., and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.